---
title: Remote Exercise for Learning Anger and Excitation Management
nct_id: NCT02132793
overall_status: COMPLETED
phase: NA
sponsor: VA Pacific Islands Health Care System
study_type: INTERVENTIONAL
primary_condition: Anger
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02132793.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02132793"
ct_last_update_post_date: 2017-11-06
last_seen_at: "2026-05-12T07:26:22.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Remote Exercise for Learning Anger and Excitation Management

**Official Title:** Remote Exercise for Learning Anger and Excitation Management (RELAX)

**NCT ID:** [NCT02132793](https://clinicaltrials.gov/study/NCT02132793)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 58
- **Lead Sponsor:** VA Pacific Islands Health Care System
- **Collaborators:** United States Department of Defense, Charles River Analytics
- **Conditions:** Anger, Stress Disorders, Post-Traumatic
- **Start Date:** 2014-03
- **Completion Date:** 2016-05
- **CT.gov Last Update:** 2017-11-06

## Brief Summary

The immediate objective of this project was to demonstrate the feasibility of Remote Exercises for Learning Anger and Excitation Management (RELAX). The application is a remote, technology- enabled, anger treatment and management system based on current evidence-based CBT interventions. The project's objective was to show that RELAX (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through the implementation of an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors and signal analysis; and (4) supports communication and direction by the therapist through a web-based therapist interface.

## Detailed Description

This project conducted a cognitive behavioral therapy (CBT) anger management treatment groups with a Veteran population using the RELAX application, collected weekly feedback from participants, and collaborate with the Sponsor to document initial efficacy, feasibility, and safety of the RELAX system. Outcome domains included: 1) clinical outcomes (symptom severity, social functioning); 2) process outcomes (perception of treatment, satisfaction, group therapy alliance, treatment compliance, and attrition and treatment credibility); and (3) Technical feasibility of the RELAX application. Study clinicians were 1) trained to conduct baseline and follow-up assessments 2) trained to conduct the standardized Anger Management Therapy (AMT) protocol at acceptable levels of adherence and competence and 3) trained how to use the technology and how to respond to technical difficulties. Study clinicians tested the feasibility of the RELAX application and showed that it can be integrated with CBT anger management therapies and support therapist communication through the technology.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* a score of 20 or higher on the 10-item Trait Scale of the STAXI
* participants taking psychoactive medications have to have a stable regimen for at least 45 days prior to study entry
* participants must be able to read, understand, and sign the consents themselves and be willing and able to comply with all study related procedures

Exclusion Criteria:

* active psychotic symptoms/disorder as determined by the Structured Clinical Interview (SCID) for Diagnostic and Statistical Manual of Mental Disorders(DSM)
* active homicidal or suicidal ideation as determined by the SCID
* any significant cognitive impairment or history of Organic Mental Disorder as determined by the SCID
* active (current) substance dependence as determined by the SCID (lifetime substance dependence or substance abuse not excluded)
* unwillingness to refrain from substance abuse during treatment
* female Veterans
* vulnerable persons such as those described in the section Ethical Considerations and Regulatory Issues, Vulnerable Population
```

## Arms

- **Anger Management Therapy** (ACTIVE_COMPARATOR) — Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
- **Anger Management Therapy & RELAX app** (EXPERIMENTAL) — Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.

## Interventions

- **Anger Management Therapy** (BEHAVIORAL) — Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
- **Anger Management Therapy & RELAX app** (BEHAVIORAL) — Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.

## Primary Outcomes

- **Dimensions of Anger Reactions (DAR-5)** _(time frame: up to 3 month follow-up)_ — The DAR-5 is a reliable and valid screening measure of common anger reactions. Its brevity is useful for rapidly assessing the presence of anger problems in different populations. The strength of the DAR-5 is that it employs a minimum number of items to measure the anger construct. Item content pertains to anger frequency, intensity, duration, interpersonal aggressiveness, and the extent to which anger interferes with interpersonal relationships.

## Secondary Outcomes

- **State-Trait Anger Expression Inventory-2 (STAXI-2)** _(time frame: Immediate post treatment and 3 month follow-up)_

## Locations (1)

- VA Pacific Islands Healthcare System, Honolulu, Hawaii, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.va pacific islands healthcare system|honolulu|hawaii|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02132793.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02132793*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*